Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Conditions: Lymphoma; Lymphoma, Mantle-Cell; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders Interventions: Biological: IM19 CAR-T cells; Drug: Cyclophosphamide; Drug: Fludarabine Sponsor: Beijing Immunochina Medical Science& Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2021 Category: Research Source Type: clinical trials
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
Condition: Liver Cancer Interventions: Biological: IM83 CAR-T cells; Combination Product: The second-line treatment of liver cancer Sponsor: Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2021 Category: Research Source Type: clinical trials